Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Core Insights - Kodiak Sciences Inc. is focused on developing transformative therapeutics for retinal diseases and will present at the J.P. Morgan Healthcare Conference on January 15, 2025 [1][2] Company Overview - Kodiak Sciences is a biopharmaceutical company dedicated to researching, developing, and commercializing therapeutics for retinal diseases, utilizing its ABC Platform™ for innovative drug design [3] - The company is advancing a portfolio of three clinical programs, with two in late-stage development and one expected to progress rapidly into pivotal studies [3] Investigational Medicines - Tarcocimab, Kodiak's lead investigational medicine, is an anti-VEGF antibody biopolymer conjugate being studied in two Phase 3 trials for diabetic retinopathy and wet AMD [4] - KSI-501 is a first-in-class bispecific antibody biopolymer conjugate targeting IL-6 and VEGF, currently in a Phase 3 study for wet AMD [5] - KSI-101 is being developed for retinal inflammatory diseases, with a Phase 1b study ongoing and plans for subsequent Phase 2b/3 studies [6] Platform Technology - Kodiak is enhancing its platform technology to incorporate small molecules and other active pharmaceutical ingredients into its biopolymer backbone, creating high drug-antibody-ratio medicines [7] - This extension, termed the ABCD Platform, aims to provide tailored modulation of biological pathways for multifactorial diseases [7]